Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

Table 5

PASI scores at each assessment timepoint during treatment (mean (SD)).

				Dose group (%)
	0.50%	1.00%	2.00%	4.00%	Vehicle
	(N=8)	(N=9)	(N=8)	(N=8)	(N=7)	P value
Day 8	7.51 (1.942)	7.96(1.870)	6.51 (3.182)	4.45 (1.897)	4.90 (1.270)
Day 15	7.43 (2.054)	7.32(1.914)	5.95 (2.941)	3.91 (1.816)	4.60 (2.022)	0.153
Day 22	6.78 (2.071)	6.69 (1.679)	5.60 (2.666)	3.45 (1.456)	4.71 (2.299)	0.04
Day 28	6.35(1.884)	6.11 (2.282)	5.96 (2.540)	3.54 (1.985)	4.33 (2.189)	0.009

, compared with baseline (day 1).